首页> 外文期刊>Journal of population therapeutics and clinical pharmacology >1Sildenafil and Furosemide Associated Ototoxicity: Consideration of Drug-Drug Interactions, Synergy, and Broader Clinical Relevance
【24h】

1Sildenafil and Furosemide Associated Ototoxicity: Consideration of Drug-Drug Interactions, Synergy, and Broader Clinical Relevance

机译:1西地那非和呋塞米相关的耳毒性:考虑药物相互作用,协同作用和更广泛的临床意义

获取原文
           

摘要

Drug-induced ototoxicity, particularly those involving phosphodiesterase type 5 (PDE-5) inhibitors, is considered to be rare and to our knowledge such an adverse effect has not been reported in Canada. Here we present a case of a 77-year old man initiated on a sildenfil regimen for the treatment of pulmonary hypertension, who developed sudden bilateral hearing loss after taking sildenafil, in the setting of high dose furosemide and diltiazem. We outline the likely interplay of patient characteristics, drug synergy and drug-drug interactions in the development of his ototoxicity. Importantly, given the extent and popularity of PDE-5 inhibitors for erectile dysfunction as well as a newer therapeutic option for pulmonary hypertension, clinicians should be aware of the risk for drug-induced ototoxicity, particularly in the setting of concomitant loop diuretics and CYP3A4 inhibiting medications.
机译:药物引起的耳毒性,特别是涉及5型磷酸二酯酶(PDE-5)抑制剂的药物引起的耳毒性被认为是罕见的,据我们所知,这种不良反应尚未在加拿大报道。在这里,我们介绍了一例77岁的老人,他接受西地那非(sildenfil)疗法治疗肺动脉高压,在服用高剂量速尿和地尔硫卓的情况下,服用西地那非后出现了突然的双侧听力丧失。我们概述了在患者耳毒性发展过程中,患者特征,药物协同作用和药物相互作用之间可能的相互作用。重要的是,考虑到PDE-5抑制剂对勃起功能障碍的程度和流行度以及肺动脉高压的新治疗选择,临床医生应意识到药物引起的耳毒性的风险,尤其是在同时使用loop利尿剂和CYP3A4抑制的情况下药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号